Latest On Alimera Sciences, Inc (ALIM):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-18 16:47 EST | News | Alimera jumps 48% on deal with EyePoint for eye disorder therapy Yutiq | N/A |  |
| 2023-05-15 20:39 EST | News | Alimera Sciences GAAP EPS of -$0.71 misses by $0.19, revenue of $13.55M beats by $1.25M | N/A | |
| 2023-04-03 17:08 EST | News | Alimera expands distribution pact for eye drug implant Iluvien to Nordic region | N/A | |
| 2023-03-31 16:50 EST | News | Alimera Sciences GAAP EPS of -$0.54 misses by $0.20, revenue of $14.03M misses by $0.59M | N/A | |
| 2023-03-31 16:50 EST | News | Alimera Sciences, Inc. (ALIM) Q4 2022 Earnings Call Transcript | N/A | |
About Alimera Sciences, Inc (ALIM):
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye read more... for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
General
- Name Alimera Sciences, Inc
- Symbol ALIM
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 130
- Last Split Factor1:15
- Last Split Date2019-11-15
- Fiscal Year EndDecember
- IPO Date2010-04-22
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.alimerasciences.com
Valuation
- Forward PE 60.61
- Price/Sales (Trailing 12 Mt.) 1.1
- Enterprise Value Revenue 2.25
- Enterprise Value EBITDA 43.18
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.12
- Next Year EPS Estimate $0.81
- Next Quarter EPS Estimate -$0.08
- Profit Margin -11%
- Operating Margin -2%
- Return on Assets -1%
- Revenue 50.82 million
- Earnings Per Share $0.30
- Revenue Per Share $9.93
- Gross Profit 43.88 million
- Quarterly Earnings Growth -20.6%
Highlights
- Market Capitalization 62.14 million
- EBITDA 1.78 million
- Analyst Target Price $14.25
- Book Value Per Share -$0.48
Share Statistics
- Shares Outstanding 5.75 million
- Shares Float 4.5 million
- % Held by Insiders 1635%
- % Held by Institutions 40.26%
- Shares Short 135864
- Shares Short Prior Month 138171
- Short Ratio 1.31
- Short % of Float 3%
- Short % of Shares Outstanding 2%
Technicals
- Beta 1.66
- 52 Week High $11.5
- 52 Week Low $2.92
- 50 Day Moving Average 8.56
- 200 Day Moving Average 5.89
Dividends
- Dividend Date 2019-11-15
- ExDividend Date N/A
- Dividend Yield 0%
Alimera Sciences, Inc (ALIM) Dividend Calendar:
ALIM's last dividend payment was made to shareholders on November 15, 2019.
Alimera Sciences, Inc (ALIM) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Alimera Sciences, Inc (ALIM) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Alimera Sciences, Inc (ALIM) Chart:
Alimera Sciences, Inc (ALIM) News:
Below you will find a list of latest news for Alimera Sciences, Inc (ALIM) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Alimera Sciences, Inc (ALIM) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Alimera Sciences, Inc (ALIM) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-04 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-03 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-11-03 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-02 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-10-28 | 8-K (Current report) | |
| 2020-09-29 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-08-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-14 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-08-04 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-30 | 8-K (Current report) | |
| 2020-07-10 | 8-K (Current report) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
Alimera Sciences, Inc (ALIM) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Alimera Sciences, Inc (ALIM). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1635%
Institutional Ownership: 4026%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-11-04 | Philip Ashman | Chief Operating Officer & SVP | Buy | 1,316.00 | 4.50 | 5,921.87 | 11,957.00 | |
| 2020-11-02 | RICHARD S JR EISWIRTH | President and CEO | Buy | 2,500.00 | 4.15 | 10,377.00 | 42,043.00 | |
| 2020-10-30 | John Philip Jones | Chief Financial Officer | Buy | 421.00 | 3.56 | 1,499.39 | 12,356.00 | |
| 2020-10-30 | David Holland | Chief Marketing Officer & SVP | Buy | 500.00 | 3.56 | 1,780.75 | 21,440.00 | |
| 2020-10-30 | RICHARD S JR EISWIRTH | President and CEO | Buy | 500.00 | 3.56 | 1,780.75 | 39,543.00 | |
| 2020-08-20 | C. Daniel Myers | Director | Sell | 5,000.00 | 6.73 | 33,650.00 | 5,578.00 | |
| 2020-04-30 | John Philip Jones | Chief Financial Officer | Buy | 167.00 | 3.61 | 603.40 | 11,935.00 | |
| 2020-04-30 | David Holland | Chief Marketing Officer & SVP | Buy | 167.00 | 3.61 | 603.40 | 20,940.00 | |
| 2020-04-30 | RICHARD S JR EISWIRTH | President and CEO | Buy | 167.00 | 3.61 | 603.40 | 39,043.00 | |
| 2020-03-18 | Philip Ashman | Chief Operating Officer & SVP | Buy | 5,389.00 | 10,641.00 | | ||
| 2020-03-18 | John Philip Jones | Chief Financial Officer | Buy | 3,958.00 | 11,768.00 | | ||
| 2020-03-18 | David Holland | Chief Marketing Officer & SVP | Buy | 5,172.00 | 20,773.00 | | ||
| 2020-03-18 | RICHARD S JR EISWIRTH | President and CEO | Buy | 10,884.00 | 38,876.00 | | ||
| 2020-03-18 | Samer Kaba | Chief Medical Officer | Buy | 4,683.00 | 8,679.00 | | ||
| 2019-12-31 | David Holland | Chief Marketing Officer & SVP | Buy | 106.00 | 7.58 | 803.48 | 18,141.00 | |
| 2019-12-31 | RICHARD S JR EISWIRTH | President and CEO | Buy | 202.00 | 7.58 | 1,531.16 | 31,908.00 | |
| 2019-12-31 | Samer Kaba | Chief Medical Officer | Buy | 93.00 | 7.58 | 704.94 | 5,672.00 | |
| 2019-12-31 | John Philip Jones | Chief Financial Officer | Buy | 78.00 | 7.58 | 591.24 | 9,686.00 | |
| 2019-12-13 | David Holland | Chief Marketing Officer & SVP | Buy | 98.00 | 8.24 | 807.52 | 18,035.00 | |
| 2019-12-13 | RICHARD S JR EISWIRTH | President and CEO | Buy | 186.00 | 8.24 | 1,532.64 | 31,706.00 | |